biomea fusion
Caroline joined Biomea in March 2021 as a consultant and in July 2021 as the Vice President of Contracts. As a California licensed attorney and French in-house counsel, Caroline brings over 20 years of experience in the biotechnology/pharmaceutical and medical device industries. Prior to Biomea, Caroline served as the Senior Director of Contracts at Dermira, a biotechnology company focused on medical dermatology from 2015 to 2021 until its acquisition by Eli Lilly and Company, and as the Associate Director, Corporate & Commercial Transactions at Pharmacyclics, a biotechnology company focused on the development of cancer therapies, from 2013 to 2015. Caroline also worked at Perseid Therapeutics-Astellas, Accuray, Maxygen, Versata and Sequoia Law Group.
Caroline holds an L.L.M in US Law from Florida Coastal School of Law and a J.D. from University of Toulouse, France.
This person is not in any teams
This person is not in any offices
biomea fusion
Biomea Fusion, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically defined cancers. The company was formed in 2017 by a small group of biotech executives that came together with the common goal of achieving better therapies for patients.